the RhoA antagonist SRGAP1 is present at subconfluent junctions to a greater extent than in confluent cultures and SRGAP1 RNAi restores RhoA signaling and contractility in subconfluent cultures to levels seen in confluent cells.
Results show that the protein expression of srGAP1 is remarkably decreased in 47.5% of colorectal cancer (CRC) tissues compared and is found to be associated with tumor progression and poor prognosis.
The elevated miR-145 present in invasive glioblastoma cells (IM3 cells) targets and down-regulated srGAP1 thereby allowing downstream G-proteins to remain in their active state and promote the observed invasive phenotype
This study proposed that the expression of SRGAP1 in the anterior neocortex may mark the early location of the human motor cortex including its corticospinal projection neurons allowing further study of their early differentiation.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.